Navigation Links
XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
Date:12/13/2010

THOUSAND OAKS, Calif., Dec. 13, 3010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA™ (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the '147 study, demonstrated that XGEVA significantly improved median bone metastasis-free survival by 4.2 months (HR=0.85, 95 percent CI 0.73-0.98, p=0.03) compared to placebo (primary endpoint), and significantly improved time to first occurrence of bone metastases (secondary endpoint). Overall survival was similar between the XGEVA and placebo groups (secondary endpoint).

Overall rates of adverse events and serious adverse events were generally similar between XGEVA and placebo, with hypocalcemia and osteonecrosis of the jaw (ONJ) observed at increased frequencies in the XGEVA arm.  The yearly rate of ONJ in the XGEVA-treated group was similar to what has been observed in prior XGEVA trials.  

"Our data demonstrate that XGEVA, which antagonizes the RANK Ligand axis, limits the ability of tumors to colonize bone, an important finding for men at risk for bone metastases and their healthcare providers," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "We look forward to presenting these landmark data at an upcoming medical conference."

The RANK Ligand pathway, first discovered by Amgen scientists in the mid-1990s, is believed to play a central role in cancer-induced bone destruction, regardless of cancer type. Data suggest that in bone metastasis, the invasion of cancer is facilitated by bone destruction. Hence, increased bone resorption due to increased RANK Ligand expression appears to augment bone metastasis.

XGEVA is a fully human monoclonal antibody that binds to RANK Ligand, a protein essential for the formation, function and
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
2. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
3. Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows
4. Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP
5. CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times
6. Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
7. Pre and Post-Operative Use of Caldolor® (Ibuprofen) Injection Significantly Reduces Pain and Opioid Use in Newly Published Study
8. Americans Confidence in Their Ability to Access and Pay for Healthcare Declines Significantly in May, According to Thomson Reuters Index
9. New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
10. Home Health Monitoring May Significantly Improve Blood Pressure Control, Kaiser Permanente Study Finds
11. Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
(Date:1/14/2014)... Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw ... with accompanying instrumentation to place and insert the screw ... soft tissue (e.g. ligament) repair or reconstruction as it ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... 26, 2011 Revenue of $374 million grew 5 ... share were $0.55 compared to $0.31 in the prior year, an increase of ... points to 13.3 percent Fiscal year 2011 ... 7 percent and earnings are expected to be $2.18 to $2.26 per diluted ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) today reported ... 31, 2010. The Company reported total revenue of $174.2 ... net product sales of $162.3 million and revenue under ... $22.9 million for the quarter ended December 31, 2010, ...
Cached Medicine Technology:Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 2Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 3Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 4Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 5Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 6Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 7Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 8Amylin Pharmaceuticals Reports 2010 Financial Results 2Amylin Pharmaceuticals Reports 2010 Financial Results 3Amylin Pharmaceuticals Reports 2010 Financial Results 4Amylin Pharmaceuticals Reports 2010 Financial Results 5Amylin Pharmaceuticals Reports 2010 Financial Results 6Amylin Pharmaceuticals Reports 2010 Financial Results 7Amylin Pharmaceuticals Reports 2010 Financial Results 8Amylin Pharmaceuticals Reports 2010 Financial Results 9
(Date:4/18/2014)... of Medicine researchers have been awarded two-year grants for ... announced this month. Of the 110 initial submissions to ... Forum Program, only four projects were funded, three of ... Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and ... professor of oncology, will use his $500,000 proof of ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Grieving children from northern Allegheny, Armstrong, Beaver, Butler, ... to be served at new facility, PITTSBURGH, Feb. ... Children, Adolescents and Their Families, announced today its,intention to ... Cranberry,area, which will aim to serve children and families ...
... For years, getting a lot of,calcium has been ... do to,prevent osteoporosis and related bone fractures. Small study ... the data from,large, prospective studies that followed people for ... 2008 issue of the Harvard,Health Letter., The ambiguity ...
... Americans who,are unaware they have diabetes or are at ... Risk Test, ALEXANDRIA, Va., Feb. 25 The ... WHAT: The American Diabetes Association will "sound the alert" ... Tuesday, March 25,2008. American Diabetes Alert Day is a ...
... reducing cross contaminations including Influenza and ... ... today introduced,the new SILVER SEAL(TM) Washable, Antimicrobial Mouse at the HiMSS,Healthcare Symposium ... world,s first computer mouse to be fully submersible,dishwasher safe, and manufactured from ...
... With Standardized Pomegranate Extract and Pomegranate Seed Oil ... and Cell Protecting Benefits, EL SEGUNDO, Calif., ... use of,pomegranate in skincare for anti-inflammatory, antioxidant and ... equal; it is,the quality of the extract that ...
... AS PART OF ... SMART HEART CHALLENGE CAMPAIGN, CHICAGO, Feb. 25 Quaker ... hearts. Thanks to thousands of,Americans who signed up to take the ... King Cardiac Foundation (LKCF).,As part of this heart healthy campaign to ...
Cached Medicine News:Health News:Highmark Caring Place to Expand Services to New Facility in Cranberry Area 2Health News:Highmark Caring Place to Expand Services to New Facility in Cranberry Area 3Health News:High Calcium Intake May Not Help Prevent Fractures, Reports The Harvard Health Letter 2Health News:Sound the Alert!!! - March 25 is the 20th Annual American Diabetes Alert(R) Day 2Health News:Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium 2Health News:Super Charge the Skin with Murad Vitalic(R) Featuring Energizing Pomegranate Complex(TM) 2Health News:Super Charge the Skin with Murad Vitalic(R) Featuring Energizing Pomegranate Complex(TM) 3Health News:King of Talk Celebrates Milestone With Quaker, The King of Hearts 2Health News:King of Talk Celebrates Milestone With Quaker, The King of Hearts 3
... The ACS:180 SE is a ... PLUS, consisting of important physical ... simplify routine operation and increase ... the "Next Generation" ACS:180. The ...
... range of Platelet aggregometers allows to ... particular needs. Single, dual and four ... recorder outputs or digital computer outputs. ... aggregometers, which measure platelet aggregation in ...
... in achieving improved cost efficiency in ... cut costs is constantly increasing. Optimize ... unnecessary manual interactions. Ensuring security of ... mechanisms like pipetting integrity check. Right ...
... The Advia 2400 ... sample volume (as low ... water consumption (40 L/hour) ... The optional universal rack ...
Medicine Products: